Literature DB >> 23239081

Loss of methylation in CpG sites in the NF-κB enhancer elements of inducible nitric oxide synthase is responsible for gene induction in human articular chondrocytes.

María C de Andrés1, Kei Imagawa, Ko Hashimoto, Antonio Gonzalez, Helmtrud I Roach, Mary B Goldring, Richard O C Oreffo.   

Abstract

OBJECTIVE: To investigate whether the abnormal expression of inducible nitric oxide synthase (iNOS) by osteoarthritic (OA) human chondrocytes is associated with changes in the DNA methylation status in the promoter and/or enhancer elements of iNOS.
METHODS: Expression of iNOS was quantified by quantitative reverse transcriptase-polymerase chain reaction. The DNA methylation status of the iNOS promoter and enhancer regions was determined by bisulfite sequencing or pyrosequencing. The effect of CpG methylation on iNOS promoter and enhancer activities was determined using a CpG-free luciferase vector and a CpG methyltransferase. Cotransfections with expression vectors encoding NF-κB subunits were carried out to analyze iNOS promoter and enhancer activities in response to changes in methylation status.
RESULTS: The 1,000-bp iNOS promoter has only 7 CpG sites, 6 of which were highly methylated in both control and OA samples. The CpG site at -289 and the sites in the starting coding region were largely unmethylated in both groups. The NF-κB enhancer region at -5.8 kb was significantly demethylated in OA samples compared with control samples. This enhancer element was transactivated by cotransfection with the NF-κB subunit p65, alone or together with p50. Critically, methylation treatment of the iNOS enhancer element significantly decreased its activity in a reporter assay.
CONCLUSION: These findings demonstrate the association between demethylation of specific NF-κB-responsive enhancer elements and the activation of iNOS transactivation in human OA chondrocytes, consistent with the differences in methylation status observed in vivo in normal and human OA cartilage and, importantly, show association with the OA process.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23239081      PMCID: PMC3937961          DOI: 10.1002/art.37806

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

Review 1.  Regulation of the expression of inducible nitric oxide synthase.

Authors:  Hartmut Kleinert; Petra M Schwarz; Ulrich Förstermann
Journal:  Biol Chem       Date:  2003 Oct-Nov       Impact factor: 3.915

Review 2.  Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?

Authors:  Theresa M Geiman; Keith D Robertson
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

3.  Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).

Authors:  Linda Vermeulen; Gert De Wilde; Petra Van Damme; Wim Vanden Berghe; Guy Haegeman
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

4.  Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages.

Authors:  S Sanjabi; A Hoffmann; H C Liou; D Baltimore; S T Smale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 5.  COX-2, NO, and cartilage damage and repair.

Authors:  A R Amin; M Dave; M Attur; S B Abramson
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

6.  Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis.

Authors:  I V Budunova; P Perez; V R Vaden; V S Spiegelman; T J Slaga; J L Jorcano
Journal:  Oncogene       Date:  1999-12-09       Impact factor: 9.867

7.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

8.  ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene.

Authors:  S Rudders; J Gaspar; R Madore; C Voland; F Grall; A Patel; A Pellacani; M A Perrella; T A Libermann; P Oettgen
Journal:  J Biol Chem       Date:  2000-10-17       Impact factor: 5.157

Review 9.  Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis.

Authors:  S B Abramson; M Attur; A R Amin; R Clancy
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

10.  Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production.

Authors:  A Hmadcha; F J Bedoya; F Sobrino; E Pintado
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  47 in total

Review 1.  Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.

Authors:  Jonathan A R Gordon; Janet L Stein; Jennifer J Westendorf; Andre J van Wijnen
Journal:  Bone       Date:  2015-03-31       Impact factor: 4.398

2.  Epigenetically mediated spontaneous reduction of NFAT1 expression causes imbalanced metabolic activities of articular chondrocytes in aged mice.

Authors:  M Zhang; Q Lu; B Egan; X-B Zhong; K Brandt; J Wang
Journal:  Osteoarthritis Cartilage       Date:  2016-02-20       Impact factor: 6.576

Review 3.  Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs.

Authors:  Yun-Rak Choi; Kelsey H Collins; Jin-Woo Lee; Ho-Jung Kang; Farshid Guilak
Journal:  Tissue Eng Regen Med       Date:  2019-01-05       Impact factor: 4.169

Review 4.  Epigenetics of osteoarticular diseases: recent developments.

Authors:  S B Roberts; E Wootton; L De Ferrari; O M Albagha; D M Salter
Journal:  Rheumatol Int       Date:  2015-03-27       Impact factor: 2.631

5.  Identification of differentially methylated regions in new genes associated with knee osteoarthritis.

Authors:  Carolina A Bonin; Eric A Lewallen; Saurabh Baheti; Elizabeth W Bradley; Michael J Stuart; Daniel J Berry; Andre J van Wijnen; Jennifer J Westendorf
Journal:  Gene       Date:  2015-10-17       Impact factor: 3.688

Review 6.  Genomics and epigenomics in rheumatic diseases: what do they provide in terms of diagnosis and disease management?

Authors:  Patricia Castro-Santos; Roberto Díaz-Peña
Journal:  Clin Rheumatol       Date:  2017-07-20       Impact factor: 2.980

7.  Analysis of methylation datasets identified significantly changed genes and functional pathways in osteoarthritis.

Authors:  Bing Han; Zhong Zheng; Jingzhong Ren; Wenqiang Qiu; Xiangwei Li
Journal:  Clin Rheumatol       Date:  2019-08-02       Impact factor: 2.980

Review 8.  Mitochondrial epigenetics in bone remodeling during hyperhomocysteinemia.

Authors:  Anuradha Kalani; Pradip K Kamat; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Mol Cell Biochem       Date:  2014-06-18       Impact factor: 3.396

Review 9.  Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2014-07-05       Impact factor: 6.730

10.  Phlpp1 facilitates post-traumatic osteoarthritis and is induced by inflammation and promoter demethylation in human osteoarthritis.

Authors:  E W Bradley; L R Carpio; M E McGee-Lawrence; C Castillejo Becerra; D F Amanatullah; L E Ta; M Otero; M B Goldring; S Kakar; J J Westendorf
Journal:  Osteoarthritis Cartilage       Date:  2015-12-31       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.